EUVIMEDEUVIMED entdecken
Crossref

Molecular profiling and personalized targeting in PDAC: implications of KRAS, BRCA, SMAD4, and emerging biomarkers

Made Ayu Kurniati Atmaja, Anak Agung Gede Cahya Wedanta, I Gede Bayu Bagus Ananda Radiasa, I Gede Aswin Parisya Sasmana, I Gede Putu Supadmanaba

Anatomy and Histology Journal of Indonesia · 25.04.2026 · 2 (1) · 12-19

DOI: 10.51559/q0507y35 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anatomy and Histology Journal of Indonesia, online erschienen am 25.04.2026. Verfasst von Made Ayu Kurniati Atmaja und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid tumors. This review synthesizes current understanding of the principal molecular drivers of PDAC, namely KRAS, BRCA1/2, and SMAD4 together with emerging biomarkers, and examines how this knowledge is being translated into personalized therapeutic strategies. A narrative review was conducted using the PubMed database to identify articles published between January 2016 and June 2026 relevant to molecular profiling and personalized targeting in PDAC. Articles were screened against predefined inclusion and exclusion criteria and synthesized thematically. KRAS, mutated in over 90% of cases (predominantly G12D), has shifted from an undruggable target to one addressed by mutation-selective and pan-RAS inhibitors, although adaptive resistance through receptor tyrosine kinase reactivation and YAP/TAZ signaling limits response durability. BRCA1/2 mutations (5–10%) confer homologous recombination deficiency and sensitivity to PARP inhibitors through synthetic lethality, with olaparib improving progression-free survival in the POLO trial. SMAD4 inactivation (50–55%), a late-stage event, functions as a prognostic biomarker associated with aggressive, metastatic disease and poorer survival. Emerging biomarkers, including circulating tumor DNA, exosomal GPC1, MSI-H/dMMR status, tumor mutational burden, rare fusions (NTRK, NRG1, FGFR2), and the Hippo-YAP/TAZ pathway, are broadening precision oncology options. KRAS, BRCA1/2, and SMAD4 each provide distinct therapeutic and prognostic information in PDAC.

Zitieren

APA

Atmaja, M. A. K., Wedanta, A. A. G. C., Radiasa, I. G. B. B. A., Sasmana, I. G. A. P., & Supadmanaba, I. G. P. (2026). Molecular profiling and personalized targeting in PDAC: implications of KRAS, BRCA, SMAD4, and emerging biomarkers. Anatomy and Histology Journal of Indonesia, 2(1), 12-19. https://doi.org/10.51559/q0507y35

Vancouver

Atmaja MAK, Wedanta AAGC, Radiasa IGBBA, Sasmana IGAP, Supadmanaba IGP. Molecular profiling and personalized targeting in PDAC: implications of KRAS, BRCA, SMAD4, and emerging biomarkers. Anatomy and Histology Journal of Indonesia. 2026;2(1):12-19. doi:10.51559/q0507y35

BibTeX
@article{Atmaja2026,
  author = {Atmaja, Made Ayu Kurniati and Wedanta, Anak Agung Gede Cahya and Radiasa, I Gede Bayu Bagus Ananda and Sasmana, I Gede Aswin Parisya and Supadmanaba, I Gede Putu},
  title = {Molecular profiling and personalized targeting in PDAC: implications of KRAS, BRCA, SMAD4, and emerging biomarkers},
  journal = {Anatomy and Histology Journal of Indonesia},
  year = {2026},
  volume = {2},
  number = {1},
  pages = {12--19},
  doi = {10.51559/q0507y35}
}
Kostenlos starten →